It is also interesting to note that 52.4% (95% CI, 38% to 66.5%) of patients with JAK2 mutation did not have a diagnosis of myeloproliferative neoplasm at presentation of SVT but were diagnosed during the follow up [23]. Here, JAK2 is linked to myeloproliferative disorder.